Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.2167 | 1 | 0.5 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.2167 | 1 | 1 |
Toxoplasma gondii | ATPase/histidine kinase/DNA gyrase B/HSP90 domain-containing protein | 0.0878 | 0 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.2167 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2167 | 1 | 0.5 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.2167 | 1 | 0.5 |
Echinococcus multilocularis | Pyruvate dehydrogenase (lipoamide) kinase | 0.2167 | 1 | 0.5 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.2167 | 1 | 0.5 |
Echinococcus granulosus | Pyruvate dehydrogenase lipoamide kinase | 0.2167 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 79.03 % | Analgesic activity in Swiss albino Mus musculus (mouse) assessed as inhibition of pain at 70 mg/kg, po measured after 4 hr by tail immersion method | ChEMBL. | No reference |
Ratio (functional) | = 0.96 | Potency index, ratio of ibuprofen analgesic activity to compound analgesic in Swiss albino Mus musculus (mouse) at 70 mg/kg, po measured after 4 hr by tail immersion method | ChEMBL. | No reference |
Time (functional) | = 2.22 s | Analgesic activity in Swiss albino Mus musculus (mouse) assessed as time required for tail withdrawal at 70 mg/kg, po measured after 4 hr by tail immersion method | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.